Theravance Biopharma Inc (TBPH)
9.34
+0.13
(+1.41%)
USD |
NASDAQ |
Apr 19, 16:00
9.34
0.00 (0.00%)
After-Hours: 19:27
Theravance Biopharma Enterprise Value: 341.17M for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 341.17M |
| April 17, 2024 | 356.10M |
| April 16, 2024 | 364.29M |
| April 15, 2024 | 375.37M |
| April 12, 2024 | 360.44M |
| April 11, 2024 | 327.68M |
| April 10, 2024 | 357.07M |
| April 09, 2024 | 354.18M |
| April 08, 2024 | 353.69M |
| April 05, 2024 | 345.99M |
| April 04, 2024 | 337.80M |
| April 03, 2024 | 345.02M |
| April 02, 2024 | 335.87M |
| April 01, 2024 | 332.50M |
| March 28, 2024 | 329.61M |
| March 27, 2024 | 331.54M |
| March 26, 2024 | 322.39M |
| March 25, 2024 | 319.50M |
| March 22, 2024 | 327.20M |
| March 21, 2024 | 329.13M |
| March 20, 2024 | 331.54M |
| March 19, 2024 | 323.83M |
| March 18, 2024 | 314.20M |
| March 15, 2024 | 313.72M |
| March 14, 2024 | 312.27M |
| Date | Value |
|---|---|
| March 13, 2024 | 321.42M |
| March 12, 2024 | 307.94M |
| March 11, 2024 | 310.35M |
| March 08, 2024 | 312.75M |
| March 07, 2024 | 316.13M |
| March 06, 2024 | 318.53M |
| March 05, 2024 | 315.16M |
| March 04, 2024 | 335.87M |
| March 01, 2024 | 352.25M |
| February 29, 2024 | 353.69M |
| February 28, 2024 | 350.32M |
| February 27, 2024 | 364.29M |
| February 26, 2024 | 342.13M |
| February 23, 2024 | 330.09M |
| February 22, 2024 | 314.76M |
| February 21, 2024 | 318.85M |
| February 20, 2024 | 326.55M |
| February 16, 2024 | 320.77M |
| February 15, 2024 | 314.52M |
| February 14, 2024 | 304.42M |
| February 13, 2024 | 299.13M |
| February 12, 2024 | 310.19M |
| February 09, 2024 | 310.19M |
| February 08, 2024 | 292.88M |
| February 07, 2024 | 306.35M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
163.25M
Minimum
Nov 02 2022
2.047B
Maximum
Apr 29 2020
1.026B
Average
1.165B
Median
Enterprise Value Benchmarks
| Corcept Therapeutics Inc | 1.980B |
| Nektar Therapeutics | -61.24M |
| Vanda Pharmaceuticals Inc | -102.30M |
| Fate Therapeutics Inc | 184.98M |
| FibroGen Inc | -7.110M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.51M |
| Revenue (Quarterly) | 17.56M |
| Total Expenses (Quarterly) | 24.16M |
| EPS Diluted (Quarterly) | -0.17 |
| Profit Margin (Quarterly) | -48.45% |
| Earnings Yield | -10.39% |
| Normalized Earnings Yield | -10.07 |